SLU-PP-332
Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator
$24
Daily dose
NOT ESTABLISHED FOR HUMANS
Frequency
Research only
Cycle length
4-8 weeks (animal studies)
Storage
Research compound
Key benefits
Exercise mimetic effects without physical activity, significant weight loss (12% in 28 days in animal studies), 70% increased endurance, 25% enhanced fatty acid oxidation, improved insulin sensitivity, reduced hepatic steatosis, cardiac protection, reversal of age-related mitochondrial dysfunction, enhanced muscle oxidative capacity. ⚠️ NOT FDA APPROVED - RESEARCH ONLY
How it works
Activates estrogen-related receptors (ERRα, ERRβ, ERRγ) which regulate energy metabolism genes. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway (cellular energy switch), increases mitochondrial density up to 1.8-fold, enhances oxidative phosphorylation, promotes fatty acid oxidation, induces oxidative muscle fiber genes, and activates acute aerobic exercise genetic programs without requiring physical activity.
Dosage protocols
Goal
⚠️ RESEARCH USE ONLY - NOT FOR HUMANS
Dose
50 mg/kg (animal dosing) · Twice daily (preclinical)
Route
IP injection (animal studies)
Goal
HUMAN DOSING NOT ESTABLISHED
Dose
Awaiting clinical trials · Not determined
Route
Oral formulation in development
Research indications
metabolic Health
cardiovascular
kidney Health
Administration
Interactions
Safety notes
⚠️ CRITICAL: NOT FDA APPROVED - FOR RESEARCH USE ONLY
⚠️ NO HUMAN CLINICAL TRIALS - all safety data from animals
Animal studies show favorable safety with no severe effects at therapeutic doses
Well-tolerated in multiple species with no liver, kidney, or cardiac toxicity
Does not suppress hormones or act as stimulant in animal models
Human safety profile COMPLETELY UNKNOWN
May interact with diabetes medications due to insulin sensitivity effects
Legal status varies - may be restricted or illegal in many jurisdictions
NEVER use experimental compounds without medical supervision
Research studies
A Synthetic ERR Agonist Alleviates Metabolic Syndrome - 2024
Diet-induced obese mice | 50 mg/kg IP twice daily | 28 days | Comprehensive metabolic assessment
Landmark study demonstrating 12% body weight loss, 25% increase in fatty acid oxidation, improved glucose tolerance, and reduced hepatic steatosis. Fat mass gain was <0.5g vs ~5g in controls. No adverse pancreatic effects observed. Published in Journal of Pharmacology and Experimental Therapeutics.
View study →Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction in Aging Kidney - 2023
21-month-old mice (equivalent to ~60-70 human years) | 8-week treatment | Comprehensive kidney function analysis
Groundbreaking aging study showing reversal of age-related kidney decline. Reduced albuminuria, prevented podocyte loss, restored mitochondrial architecture via electron microscopy, decreased inflammatory cytokines and senescence markers. First compound to directly improve mitochondrial health in aging. Published in American Journal of Pathology.
View study →Synthetic ERRα/β/γ Agonist Induces Acute Aerobic Exercise Response - 2023
Multiple mouse models | 50 mg/kg IP | Running performance and muscle fiber analysis
First demonstration that pharmacological ERR activation replicates acute exercise genetic programs. Showed 70% increase in running time, 45% increase in distance, increased type IIa oxidative muscle fibers, and progressive grip strength improvements. ERRα confirmed as critical isoform via knockout studies. Published in ACS Chemical Biology.
View study →Mitochondrial Biogenesis and Metabolic Remodeling Study - 2023
Skeletal muscle analysis | Multiple time points | Gene expression and mitochondrial function
Comprehensive analysis showing up to 1.8-fold increase in mitochondrial density in skeletal muscle, enhanced respiratory capacity, upregulation of PGC-1α and AMPK pathways, and activation of genes involved in fatty acid metabolism and oxidative phosphorylation.
Cardiac Protective Effects of Pan-ERR Agonists - 2021
Heart failure models | 6-week treatment | Cardiac function and structural analysis
Demonstrated improved ejection fraction, ameliorated cardiac fibrosis, improved survival in pressure overload-induced heart failure, enhanced mitochondrial ultrastructure, and reduced cardiac stress markers. Effects primarily mediated through ERRγ activation. Presented at Circulation.
View study →Safety and Toxicology Profiling - Ongoing
Multiple species (rodents, canines) | Various doses and durations | Comprehensive toxicology
Advanced toxicology studies showing favorable safety profile across multiple species. No liver, kidney, or cardiac toxicity reported. Well-tolerated at therapeutic doses with minimal adverse effects. No changes in lean mass, body temperature, or normal behavior patterns.